ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 105

Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey

Robert Morlock1, Natalia M. Flores2, Kathy Annunziata3, J. Chapnick4 and Sulabha Ramachandran5, 14939 Directors Place, Ardea Biosciences, San Diego, CA, 2Kantar Health, Foster City, CA, 3Kantar Health, Princeton, NJ, 4Kantar Health, Horsham, PA, 5AstraZeneca, Wilmington, DE

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Comorbidity, gout, hyperuricemia and quality of care, Work Disability

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Health Services Research

Session Type: Abstract Submissions (ACR)

Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal structures (e.g., joints), kidneys, and other connective tissues and urate crystal deposition disease, which can result in chronic inflammation leading to acute gout flares and tophi. Hyperuricemia is a metabolic disorder caused mainly by inefficient renal excretion of uric acid. Because SUA levels are often not at target, it is important to examine how this may relate to resource use and health utility. Additionally, this study examines other factors such as comorbidities and how they may exacerbate the relationship between high SUA levels, resource use, and health utility.

Methods: The data are from the combined 2012 and 2013 U.S. National Health and Wellness Survey (NHWS), a representative, cross-sectional general health survey (2012 NHWS: N = 71,157; 2013 NHWS: N = 75,000) of which 3,729 self-reported being diagnosed with gout. Those diagnosed were categorized into uncontrolled (N = 2,215) and controlled (N = 344) gout (“controlled gout” defined as: SUA ≤6 mg/dL and no flares in past year), omitting those whose control status was unknown (N = 1,170). Weights were calculated to be representative of the U.S. adult population and analyses were based on the weighted data. Resource use in the past six months, health related quality of life (SF-36v2: mental and physical component summary (MCS, PCS) and SF-6D (health utility), and work productivity loss (WPAI) were assessed across the two groups. Comorbidities (e.g., diabetes, hypertension) and their relationship to resource use and health utility were also examined.

Results: Those with uncontrolled gout reported being hospitalized (13.8% vs. 8.1%) and visiting the ER (22.3% vs. 11.7%) more than those with controlled gout. Additionally, those with uncontrolled gout reported lower MCS (Mean = 47.22 vs. Mean = 51.96), PCS (Mean = 41.95 vs. Mean = 46.32), and health utility (Mean = 0.66 vs. Mean = 0.73) scores than those with controlled gout. Furthermore, those with uncontrolled gout reported higher work productivity loss (24.5% vs 16.2%) and activity impairment (40.2% vs. 28.2%) than those with controlled gout. Having a common comorbidity with uncontrolled gout  increased resource usage compared with either 1) those uncontrolled without the comorbidity or 2) with controlled gout, as was shown with diabetes (ER visits: 27.2% vs. 13.7% and 22.6%, respectively).

Conclusion: These findings support that uncontrolled gout results in greater hospitalization and twice as many ER visits than controlled gout. This, combined with lower health utility than controlled gout, suggests a significant humanistic and economic impact. These impacts may be further compounded when comorbidities are present.


Disclosure:

R. Morlock,

Ardea Biosciences, Inc.,

1,

Ardea Biosciences, Inc.,

3;

N. M. Flores,

Kantar Health,

3;

K. Annunziata,

Kantar Health,

3;

J. Chapnick,

Kantar Health,

3;

S. Ramachandran,

AstraZeneca,

1,

AstraZeneca,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/resource-use-and-health-related-quality-of-life-burden-of-gout-exacerbated-by-common-comorbidities-results-from-the-2012-2013-national-health-and-wellness-survey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology